Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Authors: Denis Y. Logunov, Inna V. Dolzhikova, Dmitry V. Shcheblyakov, Amir I. Tukhvatulin, Olga V. Zubkova et al.